Takeda Swings to Loss on Impairment Charges, Cuts Guidance — Update
By Kosaku Narioka
Takeda Pharmaceutical cut its annual earnings forecasts as impairment charges for discontinued drug research pushed the company into the red in the latest quarter.
The Japanese drugmaker said Thursday that it swung to a net loss of 11.8 billion yen, equivalent to $77.3 million, for the three months ended September, from net profit of Y92.0 billion in the year-earlier period. The result was worse than the Y65.2 billion net profit estimate in a poll of analysts by data provider Visible Alpha.
Takeda recorded impairment charges of about Y58 billion in its second quarter related to the cell-therapy research it discontinued as part of a strategic portfolio review.
For the fiscal year ending March, it projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. The company previously expected revenue of Y4.530 trillion and net profit of Y228.00 billion.
Second-quarter revenue dropped 5.4% to Y1.113 trillion. Sales of plasma-derived products declined 2.9% to Y256.6 billion, while sales of ulcerative colitis drug Entyvio rose 3.3% to Y246.7 billion.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 30, 2025 05:39 ET (09:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
10 Best Blue-Chip Stocks to Buy for the Long Term
United States